reglab/housing_qa huggingface dataset:
IN Code § 16-42-20-9 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 20. Drugs: Enforcement of Pharmacy Laws and Rules|16-42-20-9. Research

Sec. 9. The addiction services bureau of the division of mental health and addiction shall encourage research on misuse and abuse of controlled substances. In connection with the research and in furtherance of the enforcement of laws relating to controlled substances, the bureau may do the following:(1) Establish methods to assess accurately the effects of controlled substances and identify and characterize those with potential for abuse.(2) Make studies and undertake programs of research to do the following:(A) Develop new or improved approaches, techniques, systems, equipment, and devices to strengthen the enforcement of laws relating to controlled substances.(B) Determine patterns of misuse and abuse of controlled substances and the social effects of such behavior.(C) Improve methods for preventing, predicting, understanding, and dealing with the misuse and abuse of controlled substances.(3) Enter into contracts with public agencies, postsecondary educational institutions, and private organizations or individuals for the purpose of conducting research, demonstrations, or special projects that bear directly on misuse and abuse of controlled substances.[Pre-1993 Recodification Citation: 16-6-8.5-8(b).]As added by P.L.2-1993, SEC.25. Amended by P.L.215-2001, SEC.87; P.L.2-2007, SEC.195.
IN Code § 16-42-20-10 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 20. Drugs: Enforcement of Pharmacy Laws and Rules|16-42-20-10. Contracts for Educational and Research Activities

Sec. 10. The addiction services bureau of the division of mental health and addiction may enter into contracts for educational and research activities without performance bonds.[Pre-1993 Recodification Citation: 16-6-8.5-8(c).]As added by P.L.2-1993, SEC.25. Amended by P.L.215-2001, SEC.88.
IN Code § 16-42-20-11 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 20. Drugs: Enforcement of Pharmacy Laws and Rules|16-42-20-11. Anonymity of Research Subjects

Sec. 11. The Indiana board of pharmacy may authorize persons engaged in research on the use and effects of controlled substances to withhold the names and other identifying characteristics of individuals who are the subjects of the research. Persons who obtain this authorization may not be compelled in any civil, criminal, administrative, legislative, or other proceeding to identify the individuals who are the subjects of research for which the authorization was obtained.[Pre-1993 Recodification Citation: 16-6-8.5-8(d).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-20-12 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 20. Drugs: Enforcement of Pharmacy Laws and Rules|16-42-20-12. Possession and Distribution of Controlled Substances for Research Purposes

Sec. 12. The Indiana board of pharmacy may authorize the possession and distribution of controlled substances by persons engaged in research. Persons who obtain this authorization are exempt from state prosecution for possession and distribution of controlled substances to the extent of the authorization.[Pre-1993 Recodification Citation: 16-6-8.5-8(e).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-21-1 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 21. Drugs: Drug Samples|16-42-21-1. "Controlled Substance"

Sec. 1. As used in this chapter, "controlled substance" has the meaning set forth in IC 35-48-1.[Pre-1993 Recodification Citation: 16-6-12-1.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-21-2 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 21. Drugs: Drug Samples|16-42-21-2. "Drug Sample"

Sec. 2. As used in this chapter, "drug sample" means a legend drug or a controlled substance that is manufactured, packaged, labeled, or otherwise marketed to be distributed and dispensed without consideration.[Pre-1993 Recodification Citation: 16-6-12-2.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-21-3 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 21. Drugs: Drug Samples|16-42-21-3. "Practitioner"

Sec. 3. As used in this chapter, "practitioner" means any of the following:(1) A licensed physician.(2) A dentist licensed to practice dentistry in Indiana.(3) A podiatrist licensed to practice podiatry in Indiana.(4) A veterinarian licensed to practice veterinary medicine in Indiana.(5) An optometrist who is:(A) licensed to practice optometry in Indiana; and(B) certified under IC 25-24-3.(6) An advanced practice registered nurse licensed and granted the authority to prescribe legend drugs under IC 25-23.[Pre-1993 Recodification Citation: 16-6-12-6.]As added by P.L.2-1993, SEC.25. Amended by P.L.157-2006, SEC.7; P.L.105-2008, SEC.1; P.L.129-2018, SEC.19.
IN Code § 16-42-21-4 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 21. Drugs: Drug Samples|16-42-21-4. Delivery of Drug Samples to Ultimate User After Removal From Original Packaging or After Expiration Date; Offense

Sec. 4. A person who:(1) is a manufacturer, wholesaler, practitioner, or pharmacist, or is an employee or agent of a manufacturer, wholesaler, practitioner, or pharmacist; and(2) either:(A) knowingly or intentionally removes a drug sample from its original packaging, repackages the drug sample, and delivers the drug sample to an ultimate user in exchange for money or other property; or(B) knowingly or intentionally delivers a drug sample to an ultimate user when the expiration date listed by the manufacturer on the drug sample has passed;commits a Class B misdemeanor.[Pre-1993 Recodification Citation: 16-6-12-8.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-22-1 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-1. "Brand Name"

Sec. 1. As used in this chapter, "brand name" means the proprietary or trade name selected by the drug manufacturer and placed upon a drug or the drug's container, label, or wrappings at the time of packaging.[Pre-1993 Recodification Citation: 16-6-8.1-1 part.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-22-3 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-3. "Customer"

Sec. 3. As used in this chapter, "customer" means the individual for whom a prescription is written or electronically transmitted or the individual's representative.[Pre-1993 Recodification Citation: 16-6-8.1-1 part.]As added by P.L.2-1993, SEC.25. Amended by P.L.204-2005, SEC.8.
IN Code § 16-42-22-4 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-4. "Generically Equivalent Drug Product"

Sec. 4. (a) As used in this chapter, "generically equivalent drug product" means a multiple source drug product:(1) that contains an identical quantity of identical active ingredients in the identical dosage forms (but not necessarily containing the same inactive ingredients) that meet the identical physical and chemical standards in The United States Pharmacopeia (USP) described in IC 16-42-19-2, or its supplements, as the prescribed brand name drug; and(2) if applicable, for which the manufacturer or distributor holds either an approved new drug application or an approved abbreviated new drug application unless other approval by law or of the federal Food and Drug Administration is required.(b) A drug does not constitute a generically equivalent drug product if it is listed by the federal Food and Drug Administration on or after July 1, 1987, as having actual or potential bioequivalence problems.[Pre-1993 Recodification Citation: 16-6-8.1-1 part.]As added by P.L.2-1993, SEC.25. Amended by P.L.239-1999, SEC.4.
IN Code § 16-42-22-4.5 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-4.5. "Practitioner"

Sec. 4.5. As used in this chapter, "practitioner" means any of the following:(1) A licensed physician.(2) A dentist licensed to practice dentistry in Indiana.(3) A podiatrist licensed to practice podiatric medicine in Indiana.(4) An optometrist who is:(A) licensed to practice optometry in Indiana; and(B) certified under IC 25-24-3.(5) An advanced practice registered nurse licensed and granted the authority to prescribe legend drugs under IC 25-23.As added by P.L.2-1993, SEC.25. Amended by P.L.239-1999, SEC.5; P.L.157-2006, SEC.8; P.L.129-2018, SEC.20.
IN Code § 16-42-22-5 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-5. "Substitute"

Sec. 5. As used in this chapter, "substitute" means to dispense a generically equivalent drug product in place of the brand name drug product prescribed by the practitioner.[Pre-1993 Recodification Citation: 16-6-8.1-1 part.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-22-5.5 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-5.5. Limitation of Effect of Chapter

Sec. 5.5. Nothing in this chapter authorizes any substitution other than substitution of a generically equivalent drug product.As added by P.L.239-1999, SEC.6.
IN Code § 16-42-22-6 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-6. Prescription Forms

Sec. 6. (a) Each written prescription issued by a practitioner must have two (2) signature lines printed at the bottom of the prescription form, one (1) of which must be signed by the practitioner for the prescription to be valid. Under the blank line on the left side of the form must be printed the words "Dispense as written.". Under the blank line on the right side of the form must be printed the words "May substitute.".(b) Each electronically transmitted prescription issued by a practitioner must:(1) have an electronic signature; and(2) include the electronically transmitted instructions "Dispense as written." or "May substitute.".[Pre-1993 Recodification Citation: 16-6-8.1-2(a).]As added by P.L.2-1993, SEC.25. Amended by P.L.204-2005, SEC.9.
IN Code § 16-42-22-8 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-8. Requirements for Substitution

Sec. 8. (a) For substitution to occur for a prescription other than a prescription filled under the Medicaid program (42 U.S.C. 1396 et seq.), the children's health insurance program established under IC 12-17.6-2, the biosimilar biological products requirements under IC 16-42-25, or the Medicare program (42 U.S.C. 1395 et seq.):(1) the practitioner must:(A) sign on the line under which the words "May substitute" appear; or(B) for an electronically transmitted prescription, electronically transmit the instruction "May substitute."; and(2) the pharmacist must inform the customer of the substitution.(b) This section does not authorize any substitution other than substitution of a generically equivalent drug product.[Pre-1993 Recodification Citation: 16-6-8.1-2(c).]As added by P.L.2-1993, SEC.25. Amended by P.L.239-1999, SEC.7; P.L.291-2001, SEC.233; P.L.204-2005, SEC.10; P.L.96-2014, SEC.5.
IN Code § 16-42-22-9 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-9. Transmission of Practitioner's Instructions to Pharmacist

Sec. 9. If the practitioner communicates instructions to the pharmacist orally or electronically, the pharmacist shall:(1) indicate the instructions in the pharmacist's own handwriting on the written copy of the prescription order; or(2) record the electronically transmitted instructions in an electronic format.[Pre-1993 Recodification Citation: 16-6-8.1-2(d).]As added by P.L.2-1993, SEC.25. Amended by P.L.204-2005, SEC.11.
IN Code § 16-42-22-10 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-10. Substitution Prohibited

Sec. 10. (a) If a prescription is filled under the Medicaid program (42 U.S.C. 1396 et seq.), the children's health insurance program established under IC 12-17.6-2, or the Medicare program (42 U.S.C. 1395 et seq.), the pharmacist shall substitute a generically equivalent drug product and inform the customer of the substitution if the substitution would result in a lower price unless:(1) the words "Brand Medically Necessary" or words of similar meaning are:(A) written in the practitioner's own writing on the form; or(B) electronically transmitted with an electronically transmitted prescription; or(2) the practitioner has indicated that the pharmacist may not substitute a generically equivalent drug product by:(A) orally stating that a substitution is not permitted; or(B) for an electronically transmitted prescription, indicating with the electronic prescription that a substitution is not permitted.(b) If a practitioner orally states that a generically equivalent drug product may not be substituted, the practitioner must subsequently forward to the pharmacist a written or electronically transmitted prescription with the "Brand Medically Necessary" instruction appropriately indicated in the physician's own handwriting.(c) This section does not authorize any substitution other than substitution of a generically equivalent drug product.[Pre-1993 Recodification Citation: 16-6-8.1-2(e).]As added by P.L.2-1993, SEC.25. Amended by P.L.239-1999, SEC.8; P.L.291-2001, SEC.234; P.L.204-2005, SEC.12; P.L.32-2013, SEC.1.
IN Code § 16-42-22-11 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-11. Substitution of Generic Drugs; Identification of Brand Name Drug

Sec. 11. If under this section a pharmacist substitutes a generically equivalent drug product for a brand name drug product prescribed by a practitioner, the prescription container label must identify the brand name drug for which the substitution is made and the generic drug. The identification required under this subsection must take the form of the following statement on the drug container label, with the generic name and the brand name inserted on the blank lines:"_____________ Generic for _____________".[Pre-1993 Recodification Citation: 16-6-8.1-2(f).]As added by P.L.2-1993, SEC.25. Amended by P.L.186-1993, SEC.1.
IN Code § 16-42-22-12 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 22. Drugs: Generic Drugs|16-42-22-12. Identification of Manufacturer or Distributor of Dispensed Drug Product on Prescription

Sec. 12. The pharmacist shall record on the prescription in writing or in an electronic format for an electronically transmitted prescription the name of the manufacturer or distributor, or both, of the actual drug product dispensed under this chapter.[Pre-1993 Recodification Citation: 16-6-8.1-2(g).]As added by P.L.2-1993, SEC.25. Amended by P.L.204-2005, SEC.13.
IN Code § 16-42-23-1 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-1. Health Care Facilities; Restrictions on Use

Sec. 1. Except as provided in section 8 of this chapter, a hospital or other health care facility may not interfere with the physician-patient relationship by restricting or forbidding the use of amygdalin (laetrile) as an adjunct to recognized, customary, or accepted modes of therapy in the treatment of any malignancy, disease, illness, or physical condition if the following conditions exist:(1) Amygdalin (laetrile) is prescribed or administered by a physician holding an unlimited license for the practice of medicine in Indiana.(2) The patient has signed the "written informed request" as set forth in section 5 of this chapter.[Pre-1993 Recodification Citation: 16-8-8-1.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-23-2 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-2. Disciplinary Action Against Attending Physician

Sec. 2. A physician may not be subjected to disciplinary action by the medical licensing board of Indiana for prescribing or administering amygdalin (laetrile) to a patient under the physician's care as an adjunct to recognized, customary, or accepted modes of therapy in the treatment of a malignancy, a disease, an illness, or a physical condition if the patient has signed the written informed request as set forth in section 5 of this chapter.[Pre-1993 Recodification Citation: 16-8-8-2.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-23-3 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-3. Prescription or Administration Permitted With Written Informed Request

Sec. 3. A physician may prescribe or administer amygdalin (laetrile) instead of or in addition to customary or accepted modes of therapy in the treatment of a malignancy, a disease, an illness, or a physical condition of a patient who has signed the written informed request as set forth in section 5 of this chapter.[Pre-1993 Recodification Citation: 16-8-8-3.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-23-4 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-4. Construction of Chapter

Sec. 4. (a) This chapter does not constitute an endorsement of amygdalin (laetrile) for the treatment of a malignancy, a disease, an illness, or a physical condition.(b) This chapter does not prevent a physician from prescribing amygdalin (laetrile) as a dietary supplement to a patient not suffering from a known malignancy, disease, illness, or physical condition upon execution of the written informed request.[Pre-1993 Recodification Citation: 16-8-8-4.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-23-5 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-5. Written Informed Request Form

Sec. 5. (a) The written informed request must be on a form prepared by and obtained from the medical licensing board of Indiana and must be in substance as follows:
IN Code § 16-42-23-6 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-6. Regulation of Use, Sale, Prescription, Manufacture, or Distribution Within State

Sec. 6. (a) Amygdalin (laetrile) is not a drug or a controlled substance under Indiana statutes governing the use, manufacture, or distribution of drugs and controlled substances within Indiana.(b) A physician may prescribe amygdalin (laetrile) under this chapter as a treatment that may be prescribed under IC 25-22.5-1-1.1(f).(c) The state department and the Indiana board of pharmacy may regulate the manufacture, distribution, and sale of amygdalin (laetrile) for use within Indiana only to ensure that the substance is not adulterated or misbranded within the meaning of IC 16-42-3.(d) The state department may not adopt a rule that prohibits the use of amygdalin (laetrile) in a hospital, an ambulatory outpatient surgical center, or a health care facility licensed by the state department.(e) The Indiana board of pharmacy may not adopt a rule that prohibits the manufacture, distribution, or sale of amygdalin (laetrile) by a person or in any place licensed by the Indiana board of pharmacy.[Pre-1993 Recodification Citation: 16-8-8-6.]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-23-7 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-7. Required Manufacture, Sale, Distribution, or Prescription

Sec. 7. (a) This chapter does not require a:(1) physician;(2) pharmacist;(3) pharmacy;(4) manufacturer; or(5) distributor;to manufacture, sell, or distribute amygdalin (laetrile).(b) This chapter does not require a physician to prescribe amygdalin (laetrile) for a patient.[Pre-1993 Recodification Citation: 16-8-8-7(a).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-23-8 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 23. Drugs: Use of Amygdalin (Laetrile)|16-42-23-8. Federal Funding of Health Care Facilities

Sec. 8. If:(1) the federal government indicates that the federal government will withdraw all federal funds from a health care facility for allowing amygdalin (laetrile) to be used within the facility; and(2) providing or allowing use of amygdalin (laetrile) within the facility would jeopardize the receipt of:(A) federal funds for reimbursement for Medicare or Medicaid for all persons within the facility; or(B) construction funds provided by the federal government under the Hill-Burton Hospital Construction Program (42 U.S.C. 291 et seq.) or under Title XVI of the Public Health Services Act (42 U.S.C. 300q-300t);the hospital or other health care facility may prohibit the use of amygdalin (laetrile) within the hospital or facility.[Pre-1993 Recodification Citation: 16-8-8-7(b).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-1 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-1. Record of Use

Sec. 1. The state department shall establish a record keeping system concerning the use of chymopapain and its effectiveness. The state department may require neurosurgeons and orthopedic surgeons to supply information concerning the use of chymopapain.[Pre-1993 Recodification Citation: 16-8-10-1(a).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-2 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-2. Administration Restricted

Sec. 2. Only a neurosurgeon or an orthopedic surgeon may administer chymopapain. Chymopapain may only be administered in a hospital licensed under IC 16-21-2.[Pre-1993 Recodification Citation: 16-8-10-1(b).]As added by P.L.2-1993, SEC.25.
IN Code § 16-42-24-3 (2021)
2021 Indiana Code|Title 16. Health|Article 42. Regulation of Food, Drugs, and Cosmetics|Chapter 24. Drugs: Use of Chymopapain|16-42-24-3. Hospital's Restricting or Forbidding Use Prohibited; Conditions

Sec. 3. Except as provided in section 10 of this chapter, a hospital may not interfere with the physician-patient relationship by restricting or forbidding the use of chymopapain for treatment of certain back ailments if the following conditions are met:(1) Chymopapain is administered by a neurosurgeon or an orthopedic surgeon holding an unlimited license to practice medicine in Indiana.(2) The patient has signed the request form described in section 7 of this chapter.[Pre-1993 Recodification Citation: 16-8-10-1(c).]As added by P.L.2-1993, SEC.25.